Revolution Medicines, Inc.$196.57A · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B | $5.34B | $5.16B | $4.91B |
| Cost of Revenue | $3.31B | $2.98B | $3.37B | $3.13B | $2.91B | $2.50B | $2.36B | $2.23B |
| Research & Development | $455.00M | $479.00M | $481.00M | $467.00M | $441.00M | $495.00M | $404.00M | $387.00M |
| Selling, General & Administrative | $1.71B | $1.57B | $1.63B | $1.64B | $1.62B | $1.50B | $1.46B | $1.39B |
| Operating Expenses | $5.47B | $5.02B | $5.48B | $5.23B | $4.97B | $4.49B | $4.22B | $4.01B |
| Operating Income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B | $846.00M | $941.00M | $904.00M |
| Interest Expense | $112.00M | $96.00M | $95.00M | $84.00M | $81.00M | $78.00M | $74.00M | $75.00M |
| Other Income / (Expense) | $6.00M | $49.00M | $33.00M | -$39.00M | $92.00M | $66.00M | $16.00M | $79.00M |
| Income Before Taxes | $1.44B | $1.52B | $1.34B | $1.50B | $1.36B | $842.00M | $919.00M | $946.00M |
| Provision for Income Taxes | $132.00M | $232.00M | $99.00M | $250.00M | $150.00M | $123.00M | -$152.00M | $630.00M |
| Net Income | $1.30B | $1.29B | $1.24B | $1.25B | $1.21B | $719.00M | $1.07B | $316.00M |
| Basic EPS | $4.59 | $4.44 | $4.22 | $4.19 | $3.98 | $2.33 | $3.41 | $0.98 |
| Diluted EPS | $4.57 | $4.43 | $4.19 | $4.18 | $3.94 | $2.30 | $3.37 | $0.97 |
| Basic Shares Outstanding | 284.00M | 290.00M | 294.00M | 299.00M | 304.00M | 309.00M | 314.00M | 321.00M |
| Diluted Shares Outstanding | 285.00M | 291.00M | 296.00M | 300.00M | 307.00M | 312.00M | 318.00M | 325.00M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Oct 2026 | $6.01 | $5.90 | $6.06 | 8 | ↑0 ↓0 |
| Oct 2027 | $6.59 | $6.45 | $6.68 | 8 | ↑1 ↓0 |
| Oct 2028 | $7.49 | $7.32 | $7.74 | 4 | ↑0 ↓0 |
| Oct 2029 | $9.24 | $9.24 | $9.24 | 1 | ↑0 ↓0 |
